# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: k053072   
B. Purpose for Submission: Modification to manufacturer’s existing device - addition of heparinized and EDTA plasmas as sample matrices.   
C. Measurand: Human ${ \bf { \mathfrak { a } } } _ { 1 }$ -Antitrypsin antibody   
D. Type of Test: Quantitative immunonephelometry   
E. Applicant: Dade Behring, Inc.   
F. Proprietary and Established Names: N Antisera to Human ${ \bf { \mathfrak { a } } } _ { 1 }$ -Antitrypsin   
G. Regulatory Information: 1. Regulation section: 21 CFR $\$ 866.5130$ , Alpha-1-antitrypsin immunological test systems 2. Classification: Class II 3. Product code: DEM, Alpha-1-antitrypsin, Antigen, Antiserum, Control 4. Panel: Immunology 82

# H. Intended Use:

1. Intended use:

In vitro diagnostic reagent for the quantitative determination of ${ \bf { \mathfrak { a } } } _ { 1 } .$ - antitrypsin ( $\mathrm { \Delta } [ \mathrm { a } _ { 1 } - \mathrm { \Delta } ]$ proteinase inhibitor) in human serum, heparinized and EDTA plasma by means of immunonephelometry on the $\mathbf { B N ^ { \mathrm { T M } } }$ systems.

2. Indication(s) for use: In vitro diagnostic reagent for the quantitative determination of ${ \bf { \mathfrak { a } } } _ { 1 } .$ - antitrypsin in human serum, heparinized and EDTA plasma by means of immunonephelometry on the BN™ Systems. The measurements of ${ \bf { \mathfrak { a } } } _ { 1 }$ - antitrypsin aids in the diagnosis of several conditions including adult cirrhosis of the liver. In addition, ${ \bf { \mathfrak { a } } } _ { 1 } .$ - antitrypsin deficiency has been associated with pulmonary emphysema in conjunction with other laboratory and clinical findings.

3. Special conditions for use statement(s): For prescription use only.

Special instrument requirements:   
Dade Behring BNII (k860894), BN 100 (k892223) and BN ProSpec $^ \mathrm { \textregistered }$ Nephelometer (k001647).

# I. Device Description:

The device consists of one vial containing $5 \mathrm { m L }$ or $2 \mathrm { m L }$ of N antiserum to Human ${ \bf { \mathfrak { a } } } _ { 1 }$ - antitrypsin.

# J. Substantial Equivalence Information:

1. Predicate device name(s): N Antisera to Human ${ \bf { \delta } } \mathrm { \bf { q } } _ { 1 }$ - Antitrypsin and ${ \tt a } _ { 2 }$ - Macroglobulin.

2. Predicate 510(k) number(s): k860894

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Antibody</td><td rowspan=1 colspan=1>Rabbit Anti-Human α 1-antitrypsin (polyclonal)</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Technology</td><td rowspan=1 colspan=1>Quantitative Nephelometry</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>In vitro diagnostic reagents forthe quantitative determinationof α 1- antitrypsin in humanserum, heparinized and EDTAplasma by means ofimmunonephelometry on theBNTM systems.</td><td rowspan=1 colspan=1>In vitro diagnostic reagentsfor the quantitativedetermination of α 1-antitrypsin in human serum,using the BNTM systems.</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Serum, heparinized and EDTAplasma</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Instrumentation</td><td rowspan=1 colspan=1>BNTM SystemS: BN II, BN100, and BN ProSpec®Nephelometer</td><td rowspan=1 colspan=1>BN II Nephelometer</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable): None.

# L. Test Principle:

Proteins contained in human body fluids form immune complexes in an immunochemical reaction with specific antibodies. These complexes scatter a beam of light passed through the sample. The intensity of the scattered light is proportional to the concentration of the relevant protein in the sample. The result is evaluated by comparison with a standard of known concentration.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance: a. Precision/Reproducibility: Four determinations per day over 10 days $\scriptstyle ( \mathrm { n } = 4 0$ ) were performed. The intraassay CV on the five samples (three level controls and two level pooled sera) were $1 . 8 \cdot 4 . 5 \%$ and the inter-assay CV were $1 . 1 - 2 . 5 \%$ . $b$ . Linearity/assay reportable range: No change. c. Traceability, Stability, Expected values (controls, calibrators, or methods): No change.

d. Detection limit: No change.

e. Analytical specificity:

Interference Studies:

Known interfering substances: the table below lists substances that could commonly interfere with the assay. The package insert specifies that “lipemic or turbid samples which cannot be clarified (10 minutes at approximately $1 5 , 0 0 0 { \mathrm { ~ x ~ g ) ~ } }$ must not be used”. No interferences were observed at the concentration levels tested as listed below.

<table><tr><td rowspan=1 colspan=1>Interferent</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Level Tested up to</td><td rowspan=1 colspan=1>Results</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>8.2 g/L</td><td rowspan=1 colspan=1>No interference</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>10.0 g/L</td><td rowspan=1 colspan=1>Nointerference</td></tr><tr><td rowspan=1 colspan=1>Bilirubin</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0.6 g/L</td><td rowspan=1 colspan=1>No interference</td></tr></table>

Heparin salt interference: the table below lists the three heparin salts: lithium, sodium, ammonium that could potentially interfere with the assay. No interferences were observed at the concentration levels tested as listed below.

<table><tr><td rowspan=1 colspan=1>Heparin Salt</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Level Tested up to</td><td rowspan=1 colspan=1>Results</td></tr><tr><td rowspan=1 colspan=1>Lithium</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>8.85 IU/mg</td><td rowspan=1 colspan=1>No interference</td></tr><tr><td rowspan=1 colspan=1>Sodium</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>9.05 IU/mg</td><td rowspan=1 colspan=1>No interference</td></tr><tr><td rowspan=1 colspan=1>Ammonium</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>8.45 IU/mg</td><td rowspan=1 colspan=1>No interference</td></tr></table>

f. Assay cut-off: No change.

2. Comparison studies:

a. Method comparison with predicate device: Not applicable.

$b$ . Matrix comparison: Sera and plasma samples, covering the assay measuring range (0.16 – 5.2 $\mathbf { g } / \mathrm { L } )$ were compared to determine if any significant bias existed between matrices. The heparin samples in this study had unknown salt-heparin type. The correlation coefficients were acceptable and no bias was observed.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Regression equation</td><td rowspan=1 colspan=1>r</td></tr><tr><td rowspan=1 colspan=1>Heparin</td><td rowspan=1 colspan=1>74</td><td rowspan=1 colspan=1>y = 1.0186 x - 0.0186</td><td rowspan=1 colspan=1>0.9916</td></tr><tr><td rowspan=1 colspan=1>EDTA</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>y = 0.9913 x - 0.0183</td><td rowspan=1 colspan=1>0.9948</td></tr></table>

3. Clinical studies:

a. Clinical Sensitivity: No change.

$b$ . Clinical specificity: No change.

4. Clinical cut-off: No change.

5. Expected values/Reference range: No change.

N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.